Publication:
Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens

dc.contributor.authorThanyalak Saetangen_US
dc.contributor.authorChutintorn Sriphrapradangen_US
dc.contributor.authorAngsana Phuphuakraten_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-08-25T10:42:19Z
dc.date.available2020-08-25T10:42:19Z
dc.date.issued2020-05-03en_US
dc.description.abstract© 2020 Informa UK Limited, trading as Taylor & Francis Group. Background: Hemoglobin A1c (HbA1c) has been used for the diagnosis of diabetes and glycemic monitoring. However, using HbA1c for glycemia estimation has some fallacies in anemic persons. Zidovudine (AZT) treatment is associated with anemia and/or increased mean corpuscular volume (MCV). Objective: This study aimed to compare the correlation between HbA1c and plasma glucose in HIV-infected individuals who were receiving AZT and non-AZT containing regimens. Methods: A cross-sectional study was conducted in 150 HIV-infected individuals. We evaluated the correlation of paired fasting plasma glucose (FPG), random plasma glucose (RPG), mean plasma glucose (MPG) and HbA1c values by using Pearson correlation. Multivariate linear regression was used to determine the associated factors of HbA1c. Results: The mean age was 49.0 ± 10.5 years, and 60.0% were male. Thirteen patients (8.7%) had diabetes and 14 patients (9.3%) had anemia. There were significant correlations between HbA1c and plasma glucose (FPG, RPG, and MPG; p < 0.05, all). The correlation between HbA1c and MPG in patients receiving AZT [HbA1c = 3.18 + 0.02MPG; R2=0.44] and not receiving AZT [HbA1c = 3.76 + 0.02MPG; R2=0.43] indicated that HbA1c in patients receiving AZT was 0.58% underestimated. Multivariate linear regression analysis showed that hematocrit [β 0.192; 95% confidence interval (CI) 0.003, 0.690; p = 0.032] and MCV [β −0.195; 95% CI -0.326, −0.002; p = 0.047] were associated with HbA1c levels. Conclusions: HbA1c underestimates glycemia in HIV-infected individuals receiving AZT containing regimens. Factors associated with decreased HbA1c levels in HIV-infected individuals included decreased hematocrit and increased MCV. In HIV-infected individuals receiving AZT, using HbA1c for diabetes diagnosis or glycemia monitoring should be cautiously interpreted.en_US
dc.identifier.citationHIV Research and Clinical Practice. Vol.21, No.2-3 (2020), 56-62en_US
dc.identifier.doi10.1080/25787489.2020.1766864en_US
dc.identifier.issn25787470en_US
dc.identifier.issn25787489en_US
dc.identifier.other2-s2.0-85085583011en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/58156
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085583011&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCorrelation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimensen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085583011&origin=inwarden_US

Files

Collections